Therapeutic effect of mycophenolate mofetil or cyclophosphamide in children with Henoch-Schönlein purpura nephritis of different age groups.
10.7499/j.issn.1008-8830.2306085
- Author:
Pei-Wei DU
1
;
Yu-Bing WEN
;
Chao-Ying CHEN
1
;
Juan TU
1
;
Hua-Rong LI
1
Author Information
1. Department of Nephrology, Children's Hospital Affiliated to Capital Institute of Pediatrics, Beijing 100020, China.
- Publication Type:Journal Article
- Keywords:
Child;
Cyclophosphamide;
Henoch-Schönlein purpura nephritis;
Mycophenolate mofetil;
Therapeutic efficacy
- MeSH:
Child;
Humans;
Mycophenolic Acid/adverse effects*;
IgA Vasculitis/drug therapy*;
Retrospective Studies;
Cyclophosphamide/adverse effects*;
Immunosuppressive Agents/adverse effects*;
Vasculitis/drug therapy*;
Nephritis/complications*
- From:
Chinese Journal of Contemporary Pediatrics
2023;25(11):1113-1117
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVES:To investigate the difference in the therapeutic effect of mycophenolate mofetil (MMF) or cyclophosphamide (CTX) in children with Henoch-Schönlein purpura nephritis (HSPN) of different age groups.
METHODS:A retrospective analysis was conducted on the clinical data of 135 children with HSPN who were treated with MMF or CTX in the Department of Nephrology, Children's Hospital Affiliated to Capital Institute of Pediatrics, from October 2018 to October 2020. According to the immunosuppressant used, they were divided into two groups: MMF group and CTX group, and according to the age, each group was further divided into two subgroups: ≤12 years and >12 years, producing four groups, i.e, the ≤12 years MMF subgroup (n=30), the >12 years MMF subgroup (n=15), the ≤12 years CTX subgroup (n=71), and the >12 years CTX subgroup (n=19). All children were followed up for at least 12 months, and the above groups were compared in terms of clinical outcomes and the incidence rate of adverse reactions.
RESULTS:There was no significant difference in the complete response rate between the MMF group and the CTX group after 3, 6, and 12 months of treatment (P>0.05). There were no significant difference in the complete response rate and the incidence rate of adverse reactions between the >12 years MMF subgroup and the ≤12 years MMF subgroup at 3, 6, and 12 months of treatment (P>0.05). The >12 years CTX subgroup had a significantly lower complete response rate than the ≤12 years CTX subgroup at 6 and 12 months of treatment (P<0.05). The >12 years CTX subgroup had a significantly higher incidence rate of adverse reactions than the >12 years MMF subgroup (P<0.05).
CONCLUSIONS:The efficacy and adverse reactions of MMF are not associated with age, but the efficacy of CTX is affected by age, with a higher incidence rate of adverse reactions. CTX should be selected with caution for children with HSPN aged >12 years.
